GLP-1 and CGM Convergence: Redefining the Future of Diabetes and Metabolic Health Management
The GLP-1 and CGM Convergence Market was valued at USD 1.65 billion in 2025 and is projected to reach USD 4.47 billion by 2034, registering a CAGR of 11.7% during the 2026–2034 forecast period. Market growth is driven by increasing adoption of GLP-1 therapies, declining medication costs, improved connectivity between glucose monitoring technologies and treatment platforms, and expanding insurance coverage for continuous glucose monitoring (CGM) among individuals with type 2 diabetes who are not using insulin.
Market Overview
The GLP-1 and CGM Convergence Market is emerging as an important segment of the healthcare industry, bringing together glucagon-like peptide-1 (GLP-1) receptor agonist therapies and continuous glucose monitoring (CGM) technologies to improve metabolic health management. GLP-1 medications are increasingly used to manage type 2 diabetes, obesity, and related metabolic conditions, while CGM devices provide continuous insights into glucose levels, helping patients and healthcare professionals make informed treatment decisions. The convergence of these approaches creates opportunities for more personalized, data-driven, and integrated healthcare solutions.
Growing awareness of diabetes management, increasing obesity prevalence, and rising adoption of digital health technologies are supporting market development. Pharmaceutical companies, medical device manufacturers, healthcare providers, and digital health platforms are exploring ways to combine medication management with real-time glucose monitoring. Integration of wearable sensors, mobile applications, artificial intelligence, and connected healthcare platforms is further improving patient monitoring and treatment coordination. As healthcare increasingly shifts toward personalized and preventive care, the combination of GLP-1 therapies and CGM technologies is gaining attention as a promising approach to metabolic disease management.
Key Market Growth Drivers
Increasing Prevalence of Diabetes and Obesity: The growing burden of type 2 diabetes and obesity is increasing demand for effective treatment strategies. GLP-1 therapies and CGM devices offer complementary approaches to medication-based treatment and glucose monitoring.
Rising Adoption of GLP-1 Medications: Increasing clinical use of GLP-1 receptor agonists for diabetes and weight management is creating opportunities for integrated monitoring solutions that help evaluate metabolic responses and treatment progress.
Growing Demand for Continuous Glucose Monitoring: Patients and healthcare professionals are increasingly adopting CGM technologies to understand glucose patterns, monitor daily fluctuations, and support individualized diabetes management.
Expansion of Digital Healthcare: The growing use of connected medical devices, mobile health applications, remote patient monitoring, and cloud-based healthcare platforms is supporting the integration of medication and glucose data.
Increasing Focus on Personalized Medicine: Healthcare providers are placing greater emphasis on individualized treatment decisions. Combining medication information with continuous glucose data can support more informed clinical assessments.
Key Dynamics of the GLP-1 and CGM Convergence Market
Integration of Pharmaceutical and Medical Device Technologies: Collaboration between pharmaceutical manufacturers and CGM developers is encouraging the development of connected solutions that combine treatment management with glucose monitoring.
Growth of Data-Driven Healthcare: Continuous glucose readings provide information about glucose variability, time in range, and daily metabolic patterns, creating opportunities for more comprehensive patient assessments.
Artificial Intelligence Integration: AI-powered analytics can help interpret glucose patterns, identify trends, and support healthcare professionals in evaluating patient responses to treatment.
Expansion of Remote Patient Monitoring: Connected CGM devices and digital health platforms allow healthcare professionals to review glucose information remotely, supporting ongoing patient engagement and clinical follow-up.
Increasing Clinical Research: Research examining the relationship between GLP-1 therapies, glucose regulation, weight management, and metabolic health is encouraging interest in integrated treatment monitoring approaches.
Key Players
Abbott Laboratories
Amgen Inc.
Biolinq Incorporated
Boehringer Ingelheim International GmbH
DexCom, Inc.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
MiniMed Group, Inc.
Novo Nordisk A/S
Senseonics Holdings, Inc.
Signos Inc.
𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞:
Market Challenges and Opportunities
Market Challenges
High Treatment and Device Costs: GLP-1 medications and CGM technologies can involve significant expenses, potentially limiting accessibility for patients without adequate insurance coverage or healthcare support.
Data Integration Complexity: Combining pharmaceutical treatment records, glucose readings, and electronic health records requires compatible digital infrastructure and standardized data-sharing systems.
Patient Adoption Barriers: Some patients may experience difficulties using wearable monitoring devices, understanding glucose information, or maintaining consistent treatment routines.
Regulatory and Clinical Requirements: Integrated healthcare solutions must address medical device regulations, pharmaceutical requirements, data privacy, and clinical evidence standards.
Clinical Interpretation Challenges: CGM data must be interpreted within the patient's overall clinical context, as glucose measurements alone do not provide a complete assessment of metabolic health.
Market Opportunities
Personalized Metabolic Healthcare: Combining treatment information with continuous glucose data creates opportunities for more individualized diabetes and metabolic health management.
Digital Therapeutics Development: Connected applications and healthcare platforms can support medication adherence, patient education, and lifestyle management.
Expansion into Obesity Management: Growing interest in GLP-1-based weight management is creating opportunities for broader metabolic monitoring solutions.
Strategic Industry Collaborations: Partnerships between pharmaceutical companies, CGM manufacturers, technology providers, and healthcare organizations can accelerate integrated solution development.
Emerging Healthcare Markets: Improving digital health infrastructure and increasing awareness of metabolic diseases are creating opportunities to expand access to connected healthcare technologies.
Market Segmentation
By GLP-1 Therapy Outlook (Revenue, USD Billion, 2021-2034)
Injectable GLP-1 and Dual Agonists
Oral GLP-1
Next Generation Multi Agonists
By CGM Device Outlook (Revenue, USD Billion, 2021–2034)
Prescription Wearable CGM
Over the Counter Biowearable CGM
Implantable CGM
By Patient Population Outlook (Revenue, USD Billion, 2021–2034)
Type 2 Diabetes on GLP-1
Obesity or Overweight without Diabetes
Prediabetes and Wellness
By Payment Pathway Outlook (Revenue, USD Billion, 2021–2034)
Medicare and Medicaid
Commercial Insurance
Self Pay
Future Outlook
The future of the GLP-1 and CGM Convergence Market will be shaped by increasing demand for personalized metabolic healthcare, expanding adoption of connected medical devices, and continued innovation in pharmaceutical treatments. As GLP-1 therapies become more widely integrated into diabetes and obesity management, the role of continuous monitoring and digital health platforms is expected to receive greater attention.
Advancements in wearable sensors, cloud-based healthcare systems, artificial intelligence, and remote patient monitoring will support the development of more connected treatment ecosystems. These technologies can help healthcare professionals understand glucose patterns, monitor treatment progress, and improve communication with patients.
Pharmaceutical companies and medical device manufacturers are also expected to strengthen collaborations to develop integrated healthcare solutions. Greater clinical research and improved interoperability between digital platforms will be important for establishing the effectiveness and practical value of these approaches.
Overall, the convergence of GLP-1 therapies and continuous glucose monitoring represents an emerging direction in metabolic healthcare. By combining pharmacological treatment with continuous health data, this evolving market has the potential to support more informed, personalized, and coordinated approaches to diabetes and metabolic disease management.

Comments